Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

The COVID-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Single and combination monoclonal antibody (mAb) therapeutics have received emergency use authorization(1–3), wit...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:bioRxiv
Auteurs principaux: Wang, Pengfei, Nair, Manoj S., Liu, Lihong, Iketani, Sho, Luo, Yang, Guo, Yicheng, Wang, Maple, Yu, Jian, Zhang, Baoshan, Kwong, Peter D., Graham, Barney S., Mascola, John R., Chang, Jennifer Y., Yin, Michael T., Sobieszczyk, Magdalena, Kyratsous, Christos A., Shapiro, Lawrence, Sheng, Zizhang, Huang, Yaoxing, Ho, David D.
Format: Artigo
Langue:Inglês
Publié: Cold Spring Harbor Laboratory 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7852271/
https://ncbi.nlm.nih.gov/pubmed/33532778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.01.25.428137
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires